{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:06:41Z","timestamp":1785870401213,"version":"3.56.0"},"reference-count":41,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mem. Inst. Oswaldo Cruz"],"abstract":"<jats:p>Tuberculosis (TB) is a preventable and curable disease caused by the bacillus Mycobacterium tuberculosis. In 2022, according to the World Health Organisation (WHO), TB was the second leading cause of death worldwide caused by a single infectious agent, after coronavirus disease (COVID-19). Brazil is ranked among the 30 countries with the highest TB burden. Currently, the neonatal Bacillus Calmette-Gu\u00e9rin (BCG) is the only vaccine against TB and offers significant efficacy against disseminated and meningeal disease in children. However, BCG has a limited efficacy in preventing adult-type cavitary TB, reinforcing the need for a new effective vaccine against pulmonary TB. There are currently over 22 TB vaccines under evaluation in clinical trials worldwide. Despite significant advancements, several challenges persist in developing and producing an effective TB vaccine. These include understanding the immune mechanisms that confer protection against M. tuberculosis, identifying immune correlates of protection, defining immune responses in BCG-vaccinated individuals, establishing efficacy endpoints for TB vaccine trials, and ensuring vaccine safety and effectiveness in individuals with human immunodeficiency virus (HIV), among other obstacles. Therefore, this study aims to explore the key obstacles in developing new TB vaccines and potential strategies to overcome them.<\/jats:p>","DOI":"10.1590\/0074-02760240236","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T20:39:13Z","timestamp":1749501553000},"source":"Crossref","is-referenced-by-count":8,"title":["Challenges in developing new tuberculosis vaccines"],"prefix":"10.1590","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1950-1190","authenticated-orcid":false,"given":"Gabriela","family":"Sadigurschi","sequence":"first","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz-Fiocruz,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina Caetano","family":"Kuschnir","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz-Fiocruz,  Brazil; Universidade do Estado do Rio de Janeiro,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewerton Alves Portela","family":"dos Santos","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz-Fiocruz,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Rangel Antunes","family":"da Silva","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz-Fiocruz,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia Menezes Cruz","family":"Marques","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz-Fiocruz,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raissa Coelho","family":"de Andrade","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz-Fiocruz,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarice Monteiro","family":"Vianna","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz-Fiocruz,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danillo Gon\u00e7alves","family":"de Barros","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz-Fiocruz,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Torres","family":"Mazzi","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz-Fiocruz,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira Alonso","family":"Lago","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz-Fiocruz,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliane Matos","family":"dos Santos","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz-Fiocruz,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria de Lourdes de Sousa","family":"Maia","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz-Fiocruz,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","series-title":"Global Tuberculosis Report 2023","year":"2023"},{"key":"ref2","article-title":"Dados epidemiol\u00f3gicos da tuberculose no Brasil","year":"2024","journal-title":"Minist\u00e9rio da Sa\u00fade"},{"key":"ref3","series-title":"StatPearls","first-page":"s","volume-title":"Bacillus Calmette Guerin","author":"Okafor CN","year":"2025"},{"issue":"43","key":"ref4","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.1016\/j.vaccine.2019.08.067","article-title":"BCG vaccine and leprosy household contacts protective effect and probability to becoming sick during follow-up","volume":"37","author":"Gomes RR","year":"2019","journal-title":"Vaccine"},{"issue":"9","key":"ref5","doi-asserted-by":"crossref","first-page":"e1307","DOI":"10.1016\/S2214-109X(22)00283-2","article-title":"Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course a systematic review and individual participant data meta-analysis","volume":"10","author":"Martinez L","year":"2022","journal-title":"Lancet Glob Health"},{"key":"ref6","year":"2023"},{"key":"ref7","year":"2015"},{"key":"ref8","article-title":"plano nacional pelo fim da tuberculose como problema de sa\u00fade p\u00fablica: estrat\u00e9gias para 2021-2025","year":"2024","journal-title":"Minist\u00e9rio da Sa\u00fade"},{"key":"ref9","article-title":"WHO preferred product characteristics for new tuberculosis vaccine","year":"2018","journal-title":"World Health Organization"},{"issue":"106987","key":"ref10","doi-asserted-by":"crossref","first-page":"106987","DOI":"10.1016\/j.ijid.2024.106987","article-title":"Perspectives on development and advancement of new tuberculosis vaccines","volume":"141S","author":"da Costa C","year":"2024","journal-title":"Int J Infect Dis"},{"issue":"43","key":"ref11","doi-asserted-by":"crossref","first-page":"15520","DOI":"10.1073\/pnas.1404386111","article-title":"Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries","volume":"111","author":"Knight GM","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1590\/0074-02760240093","article-title":"Advances in the development of new vaccines for tuberculosis and Brazil's role in the effort forward the end TB strategy","volume":"119","author":"Junqueira-Kipnis AP","year":"2024","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1440935","DOI":"10.3389\/fimmu.2024.1440935","article-title":"From pathogenesis to antigens the key to shaping the future of TB vaccines","volume":"15","author":"Yang H","year":"2024","journal-title":"Front Immunol"},{"key":"ref14","article-title":"Immunology of Mycobacterium tuberculosis infections","author":"Sia JK","year":"2019","journal-title":"Microbiol Spectr"},{"key":"ref15","article-title":"A functional role for antibodies in tuberculosis","author":"Lu LL","year":"2016","journal-title":"Cell"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1238649","DOI":"10.3389\/fimmu.2023.1238649","article-title":"Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates","volume":"14","author":"Zhou F","year":"2023","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2017.05.012","article-title":"Antigen availability shapes T cell differentiation and function during tuberculosis","author":"Moguche AO","year":"2017","journal-title":"Cell Host Microbe"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"11290","DOI":"10.1038\/ncomms11290","article-title":"T-cell activation is an immune correlate of risk in BCG vaccinated infants","volume":"7","author":"Fletcher HA","year":"2016","journal-title":"Nat Commun"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.1093\/jpids\/piac078","article-title":"What's old and new in tuberculosis vaccines for children","author":"Cranmer LM","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/s41590-021-01066-1","article-title":"Robust IgM responses following intravenous vaccination with Bacille Calmette-Gu\u00e9rin associate with prevention of Mycobacterium tuberculosis infection in macaques","volume":"22","author":"Irvine EB","year":"2021","journal-title":"Nat Immunol"},{"issue":"8","key":"ref21","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s10096-020-03843-6","article-title":"Tuberculosis vaccine development from classic to clinical candidates","volume":"39","author":"Li J","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.vaccine.2021.01.068","article-title":"Can what have we learnt about BCG vaccination in the last 20 years help us to design a better tuberculosis vaccine","volume":"40","author":"Dockrell HM","year":"2022","journal-title":"Vaccine"},{"issue":"10","key":"ref23","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1016\/j.celrep.2016.11.011","article-title":"Immunometabolic pathways in BCG-induced trained immunity","volume":"17","author":"Arts RJW","year":"2016","journal-title":"Cell Rep"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008404","article-title":"New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumonia","volume":"16","author":"Taranc\u00f3n R","year":"2020","journal-title":"PLoS Pathog"},{"issue":"164","key":"ref25","doi-asserted-by":"crossref","first-page":"220044","DOI":"10.1183\/16000617.0044-2022","article-title":"End-point definition and trial design to advance tuberculosis vaccine development","volume":"31","author":"Garcia-Basteiro AL","year":"2022","journal-title":"Eur Respir Rev"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1128\/MMBR.00021-14","article-title":"Tuberculosis vaccines and prevention of infection","volume":"78","author":"Hawn TR","year":"2014","journal-title":"Microbiol Mol Biol Rev"},{"issue":"8","key":"ref27","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/infdis\/jit647","article-title":"Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination","volume":"209","author":"Harris SA","year":"2014","journal-title":"J Infect Dis"},{"issue":"10","key":"ref28","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1164\/rccm.201908-1580OC","article-title":"A human lung challenge model to evaluate the safety and immunogenicity of PPD and live Bacillus calmette-Gu\u00e9rin","volume":"201","author":"Davids M","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"ref29","doi-asserted-by":"crossref","first-page":"dmm045716","DOI":"10.1242\/dmm.045716","article-title":"Integrating fish models in tuberculosis vaccine development","volume":"13","author":"Saralahti AK","year":"2020","journal-title":"Dis Model Mech"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"a018556","DOI":"10.1101\/cshperspect.a018556","article-title":"Mouse model of tuberculosis","volume":"5","author":"Cooper AM","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/ilar\/ilx015","article-title":"Translational research in the nonhuman primate model of tuberculosis","volume":"58","author":"Foreman TW","year":"2017","journal-title":"ILAR J"},{"issue":"10","key":"ref32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003485","article-title":"Natural variation in immune responses to neonatal Mycobacterium bovis Bacillus Calmette-Guerin (BCG) Vaccination in a Cohort of Gambian infants","volume":"3","author":"Finan C","year":"2008","journal-title":"PLoS One"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fcimb.2020.00139","article-title":"Challenges of immune response diversity in the human population concerning new tuberculosis diagnostics, therapies, and vaccines","volume":"10","author":"Azad AK","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"ref34","article-title":"Portaria n\u00ba 1.533, de 18 de agosto de 2016. Redefine o Calend\u00e1rio Nacional de Vacina\u00e7\u00e3o, o Calend\u00e1rio Nacional de Vacina\u00e7\u00e3o dos Povos Ind\u00edgenas e as Campanhas Nacionais de Vacina\u00e7\u00e3o, no \u00e2mbito do Programa Nacional de Imuniza\u00e7\u00f5es (PNI), em todo o territ\u00f3rio nacional","year":"2016","journal-title":"Di\u00e1rio Oficial da Uni\u00e3o"},{"issue":"11","key":"ref35","doi-asserted-by":"crossref","first-page":"e791","DOI":"10.1016\/S2352-3018(22)00255-7","article-title":"Developing tuberculosis vaccines for people with HIV consensus statements from an international expert panel","volume":"9","author":"Miner MD","year":"2022","journal-title":"Lancet HIV"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40471-021-00269-2","article-title":"New developments and insights in the improvement of Mycobacterium tuberculosis vaccines and diagnostics within the End TB strategy","volume":"8","author":"Garc\u00eda JI","year":"2021","journal-title":"Curr Epidemiol Rep"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3389\/fmicb.2020.01339","article-title":"Respiratory immunization with a whole cell inactivated vaccine induces functional mucosal immunoglobulins against tuberculosis in mice and non-human primates","volume":"11","author":"Aguilo N","year":"2020","journal-title":"Front Microbiol"},{"issue":"10","key":"ref38","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(14)70845-X","article-title":"Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults a phase 1, double-blind, randomised controlled trial","volume":"14","author":"Satti I","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"ref39","doi-asserted-by":"crossref","first-page":"106205","DOI":"10.1016\/j.jinf.2024.106205","article-title":"Randomised, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route","volume":"89","author":"Audran R","year":"2024","journal-title":"J Infect"},{"issue":"100267","key":"ref40","doi-asserted-by":"crossref","first-page":"100267","DOI":"10.1016\/j.jvacx.2023.100267","article-title":"Meeting report 6th global forum on tuberculosis vaccines, 22-25 February 2022, Toulouse, France","volume":"13","author":"Young C","year":"2023","journal-title":"Vaccine X"},{"issue":"50","key":"ref41","doi-asserted-by":"crossref","first-page":"7223","DOI":"10.1016\/j.vaccine.2021.08.094","article-title":"Meeting report Virtual Global Forum on Tuberculosis Vaccines, 20-22 April 2021","volume":"39","author":"Suliman S","year":"2021","journal-title":"Vaccine"}],"container-title":["Mem\u00f3rias do Instituto Oswaldo Cruz"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0074-02762025000100853&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T20:39:18Z","timestamp":1749501558000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0074-02762025000100853&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":41,"alternative-id":["S0074-02762025000100853"],"URL":"https:\/\/doi.org\/10.1590\/0074-02760240236","relation":{},"ISSN":["1678-8060","0074-0276"],"issn-type":[{"value":"1678-8060","type":"electronic"},{"value":"0074-0276","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"e240236"}}